Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959563 · ClinicalTrials.gov registry record · Early Phase 1
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
A Early Phase 1 study of HPV Infection, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06959563 is a Early Phase 1 study of HPV Infection that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 20 participants, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06959563, a Early Phase 1 study of HPV Infection, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Conditions Studied
Interventions
- BIOLOGICAL 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
Study Locations (1)
Maryland
- Medicine Invention Design, Inc. - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-09-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959563
The ClinicalTrials.gov registry entry for NCT06959563 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (91% lower). The listed sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV Infection appearing as the primary indexed condition, and to 1 intervention - of which 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use is the first listed.
NCT06959563 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06959563 about?
NCT06959563 is a clinical study titled "Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV". Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation...
What is the current status of trial NCT06959563?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-28. Estimated completion is 2026-09-28.
What conditions does trial NCT06959563 study?
This clinical trial studies the following conditions: HPV Infection.
What interventions are being tested in trial NCT06959563?
The interventions under investigation include: 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use (BIOLOGICAL).
Who is sponsoring clinical trial NCT06959563?
This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959563 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
RECRUITING
-
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.